2m 2m 2m 2m 2m 2m 2m
Spyre Therap (SYRE)
NASDAQ
$88.66-$11.66 (-11.63%)
Price as of Jun 23, 2026 5:03 PM EDT- $8.7BMarket Cap
- 583.38%1-Year Change
- BiotechnologyIndustry
Spyre Therap (SYRE)
$88.66-$11.66 (-11.63%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 0 N/A | 0 -100.00% | 886,000 -61.96% | 2.3M -87.57% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 -100.00% | 886,000 -61.96% | 2.3M -87.57% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -171.7M +5.44% | -162.8M +81.88% | -89.5M +52.79% | -58.6M +2.65% | |
Depreciation and Amortization Expense | 0 N/A | 0 -100.00% | 744,000 -52.52% | 1.6M -0.57% | |
Total Operating Expenses | 209.6M +0.48% | 208.6M -14.24% | 243.2M +179.17% | 87.1M +3.23% | |
Operating Profit | -209.6M +0.48% | -208.6M -13.92% | -242.3M +185.80% | -84.8M +29.14% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Total Nonoperating Income and Expense | 54.3M +8,972.45% | 599,000 +100.62% | -96.5M -11,728.07% | 830,000 +7,645.45% | |
Income before Taxes | -155.2M -25.36% | -208.0M -38.62% | -338.8M +303.59% | -84.0M +27.86% | |
Income Taxes | -15,000 -129.41% | 51,000 +296.15% | -26,000 -80.88% | -136,000 -196.45% | |
Extraordinary Items | 0 N/A | 0 -100.00% | 2.6M N/A | N/A N/A | |
Net Income | -155.2M -25.39% | -208.0M -38.60% | -338.8M +304.21% | -83.8M +27.38% | |
Net Income from Continuing Operations Applicable to Common | -155.2M -25.36% | -208.0M -38.62% | -338.8M +303.59% | -84.0M +27.86% | |
Basic EPS and Net Income | -79.02 +2,384.91% | -3.18 -123.11% | 13.76 +1,489.90% | -0.99 -1.00% | |
Diluted EPS and Net Income | -79.02 +2,384.91% | -3.18 -123.11% | 13.76 +1,489.90% | -0.99 -1.00% | |
Basic Weighted Average Shares | 346,045 -99.26% | 47.0M +581.85% | 6.9M -91.82% | 84.3M +28.19% | |
Diluted Weighted Average Shares | 346,045 -99.26% | 47.0M +581.85% | 6.9M -91.82% | 84.3M +28.19% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 85.7M -4.14% | 89.4M -52.66% | 188.9M +441.82% | 34.9M +130.24% | |
Short-Term Investments | 670.8M +30.59% | 513.7M +241.57% | 150.4M +621.34% | 20.8M -73.27% | |
Cash and Cash Equivalents and Short-Term Investments | 756.5M +25.44% | 603.1M +77.76% | 339.3M +508.99% | 55.7M -40.18% | |
Total Current Assets | 777.8M +27.82% | 608.5M +78.16% | 341.5M +448.57% | 62.3M -37.04% | |
Accumulated Depreciation | N/A N/A | N/A N/A | 0 -100.00% | 4.1M +47.89% | |
Property and Plant and Equipment and Net | N/A N/A | N/A N/A | 0 -100.00% | 3.2M -29.22% | |
Total Long-Term Assets | 0 -100.00% | 10,000 +11.11% | 9,000 -98.68% | 683,000 -18.88% | |
Total Assets | 777.8M +27.82% | 608.5M +77.99% | 341.9M +380.52% | 71.1M -35.28% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | 1.5M 0.00% | |
Total Current Liabilities | 58.7M +8.56% | 54.1M +69.05% | 32.0M +118.19% | 14.7M -27.24% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 3.9M -89.46% | 36.6M -11.35% | 41.3M N/A | 0 -100.00% | |
Total Liabilities | 62.5M -31.03% | 90.7M +23.73% | 73.3M +251.69% | 20.8M -19.80% | |
Retained Earnings | -1.1B +15.96% | -972.4M +27.21% | -764.4M +79.60% | -425.6M +24.52% | |
Total Stockholders Equity | 715.2M +38.13% | 517.8M +181.39% | 184.0M +265.80% | 50.3M -40.07% | |
Total Shares Outstanding | 78.2M +29.76% | 60.3M +67.12% | 36.1M -44.82% | 65.4M +32.41% | |
Cash Flow | |||||
Cash from Operating Activities | -169.3M +7.52% | -157.4M +57.55% | -99.9M +24.66% | -80.1M +49.20% | |
Capital Expenditures | N/A N/A | 0 N/A | 0 -100.00% | 38,000 -93.37% | |
Cash from Investing Activities | -143.5M -59.39% | -353.3M +225.93% | -108.4M -290.14% | 57.0M +352.04% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 309.0M -24.79% | 410.9M +13.80% | 361.1M +746.05% | 42.7M +2,963.75% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | -27,347.97% +651.27% | -3,640.23% +939.08% | |
Return on Assets | -22.39% -48.85% | -43.78% -73.32% | -164.06% +77.22% | -92.58% +91.02% | |
Return on Equity | -25.17% -57.53% | -59.28% -79.50% | -289.17% +131.58% | -124.87% +112.32% | |
Revenue Growth | N/A N/A | -100.00% +61.40% | -61.96% -29.25% | -87.57% N/A | |
Current Ratio | 13.25 +17.75% | 11.26 +5.39% | 10.68 +151.41% | 4.25 -13.47% | |
Cash Ratio | 1.46 -11.69% | 1.65 -72.00% | 5.91 +148.32% | 2.38 +216.46% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow